LNTH
Lantheus Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LNTH
Lantheus Holdings, Inc.
A company that develops diagnostic medical imaging agents and products for the diagnosis of cardiovascular and other diseases
Healthcare Equipment and Supplies
--
06/25/2015
NASDAQ Stock Exchange
808
12-31
Common stock
201 Burlington Road, South Building, Bedford, MA 01730
--
Lantheus Holdings, Inc., was founded in 2007 in Delaware and is headquartered in North Billerica, Massachusetts. The company is a global leader in the development, production, sales and distribution of innovative medical imaging diagnostic reagents and products to assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's reagents are commonly used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. Clinicians use the company's imaging agents and products through a range of imaging methods, including nuclear imaging, echocardiography and magnetic resonance imaging, or MRI. The Company believes that improved diagnostic information enables healthcare services to provide better detection and characterization, or to exclude diseases, which may result in improved patient conditions, reduced patient risk, and limited overall taxpayer costs and the healthcare system as a whole.
Earnings Call
Q1/2025
Estimate EPS1.65
Actual EPS1.53
Estimate Revenue379.14M
Actual Revenue372.76M
Navigating Contradictions: PYLARIFY's Competitive Landscape and Growth Expectations in 2025
May 07,2025 07:24
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.68
Actual EPS1.57
Estimate Revenue387.94M
Actual Revenue378.04M
Lantheus' Q2 2025 Earnings Call: Unpacking Contradictions in PYLARIFY's Market Position and Growth Strategies
Aug 06,2025 11:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LNTH has released its 2025 Q3 earnings. EPS was reported at 1.27, versus the expected 1.27, meeting expectations. The chart below visualizes how LNTH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LNTH has released its 2025 Q3 earnings report, with revenue of 384.01M, reflecting a YoY change of 1.39%, and net profit of 27.77M, showing a YoY change of -78.82%. The Sankey diagram below clearly presents LNTH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
